MX2018011893A - Gel viscoelastico de liraglutida adaptado para una administracion semanal o quincenal. - Google Patents

Gel viscoelastico de liraglutida adaptado para una administracion semanal o quincenal.

Info

Publication number
MX2018011893A
MX2018011893A MX2018011893A MX2018011893A MX2018011893A MX 2018011893 A MX2018011893 A MX 2018011893A MX 2018011893 A MX2018011893 A MX 2018011893A MX 2018011893 A MX2018011893 A MX 2018011893A MX 2018011893 A MX2018011893 A MX 2018011893A
Authority
MX
Mexico
Prior art keywords
once
weekly
gel
liraglutide
viscoelastic gel
Prior art date
Application number
MX2018011893A
Other languages
English (en)
Inventor
Patel Vivek
Halder Arindam
Jaysingh Khopade Ajay
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2018011893A publication Critical patent/MX2018011893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

La presente invencion se relaciona a un gel viscoelastico que comprende una cantidad terapeuticamente eficaz de liraglutida, en donde el gel no tiene un copolimero de bloque o de injerto, y en donde el gel es caracterizado por el valor de rendimiento de 200 Pa a 3000 Pa y punto de flujo de 300 Pa a 3500 Pa. La invencion tambien proporciona un metodo para controlar los niveles de azucar en sangre administrando subcutaneamente dicho gel semanalmente o quincenalmente a un sujeto en necesidad del mismo. Tambien se proporciona el metodo de preparacion de dichos geles.
MX2018011893A 2016-03-31 2016-12-16 Gel viscoelastico de liraglutida adaptado para una administracion semanal o quincenal. MX2018011893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621011454 2016-03-31
PCT/IN2016/050447 WO2017168435A1 (en) 2016-03-31 2016-12-16 Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration

Publications (1)

Publication Number Publication Date
MX2018011893A true MX2018011893A (es) 2019-01-10

Family

ID=59963648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011893A MX2018011893A (es) 2016-03-31 2016-12-16 Gel viscoelastico de liraglutida adaptado para una administracion semanal o quincenal.

Country Status (10)

Country Link
US (1) US20190105268A1 (es)
EP (1) EP3436050A4 (es)
JP (1) JP2019510048A (es)
CN (1) CN108883157A (es)
AU (1) AU2016400406A1 (es)
BR (1) BR112018069591A2 (es)
CA (1) CA3018670A1 (es)
MX (1) MX2018011893A (es)
RU (1) RU2018134132A (es)
WO (1) WO2017168435A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260300A1 (en) 2018-06-01 2021-08-26 Sun Pharma Advanced Research Company Limited An injection device
KR102583029B1 (ko) * 2020-05-28 2023-09-26 주식회사 아울바이오 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법
WO2023189270A1 (ja) * 2022-03-28 2023-10-05 富士フイルム株式会社 生体用組成物
WO2023189273A1 (ja) * 2022-03-28 2023-10-05 富士フイルム株式会社 生体用組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594718C (en) * 2005-01-14 2012-01-24 Camurus Ab Gnrh analogue formulations
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
EP1891941A1 (en) * 2006-08-11 2008-02-27 OctoPlus Technologies B.V. Aqueous gels comprising microspheres
JP2014502985A (ja) * 2011-01-19 2014-02-06 ノヴォ ノルディスク アー／エス Ｇｌｐ−１粒子および組成物
SG11201402673YA (en) * 2011-12-05 2014-06-27 Camurus Ab Robust controlled-release formulations
US9314422B2 (en) * 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
CN104069485A (zh) * 2013-03-27 2014-10-01 深圳翰宇药业股份有限公司 一种利拉鲁肽原位凝胶制剂及其制备方法
CN104840415B (zh) * 2014-02-19 2019-03-15 香港浸会大学 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法

Also Published As

Publication number Publication date
WO2017168435A1 (en) 2017-10-05
JP2019510048A (ja) 2019-04-11
EP3436050A1 (en) 2019-02-06
US20190105268A1 (en) 2019-04-11
CN108883157A (zh) 2018-11-23
EP3436050A4 (en) 2020-01-15
RU2018134132A (ru) 2020-04-30
CA3018670A1 (en) 2017-10-05
AU2016400406A1 (en) 2018-10-04
BR112018069591A2 (pt) 2019-04-16

Similar Documents

Publication Publication Date Title
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
EP3607074A4 (en) REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
GEP20217328B (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2018011893A (es) Gel viscoelastico de liraglutida adaptado para una administracion semanal o quincenal.
WO2016172658A3 (en) Microbiome regulators and related uses thereof
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
GEP20217249B (en) Stable liquid pharmaceutical preparation
WO2015077540A3 (en) Compositions and methods for treating pulmonary hypertension
MY188696A (en) Cysteine protease
WO2018026722A8 (en) COMPOSITIONS AND METHODS FOR INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
WO2018226992A8 (en) Tau aggregation inhibitors
NZ756936A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
BR112017023762A2 (pt) formulações de depósito injetáveis
MX2017016418A (es) Composiciones de liraglutida de acción prolongada.
WO2017146792A8 (en) Compositions of bioactive fulvate fractions and uses thereof
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
PH12020551618A1 (en) Erenumab compositions and uses thereof
WO2018136779A3 (en) OXALOBACTER FORMIGENES(Of)-DERIVED FACTORS FOR THE TREATMENT OF TREATMENT/PREVENTION OF EXCESS OXALATE LEVELS